These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

840 related items for PubMed ID: 31326358

  • 1. Impact of Overactive Bladder-Wet Syndrome on Female Sexual Function: A Systematic Review and Meta-Analysis.
    Balzarro M, Rubilotta E, Mancini V, Trabacchin N, Oppezzi L, Li Marzi V, Fusco F, Serati M.
    Sex Med Rev; 2019 Oct; 7(4):565-574. PubMed ID: 31326358
    [Abstract] [Full Text] [Related]

  • 2. OnabotulinumtoxinA detrusor injection improves female sexual function in women with overactive bladder wet syndrome.
    Balzarro M, Rubilotta E, Braga A, Bassi S, Processali T, Artibani W, Serati M.
    Eur J Obstet Gynecol Reprod Biol; 2018 Jun; 225():228-231. PubMed ID: 29753213
    [Abstract] [Full Text] [Related]

  • 3. Percutaneous Tibial Nerve Stimulation Improves Female Sexual Function in Women With Overactive Bladder Syndrome.
    Musco S, Serati M, Lombardi G, Lumi E, Parisi AI, Del Popolo G, Finazzi Agrò E.
    J Sex Med; 2016 Feb; 13(2):238-42. PubMed ID: 26803455
    [Abstract] [Full Text] [Related]

  • 4. Impact of intravesical onabotulinumtoxinA (Botox) on sexual function in patients with overactive bladder syndrome: a systematic review and meta-analysis.
    Shawer S, Khunda A, Waring GJ, Ballard P.
    Int Urogynecol J; 2022 Feb; 33(2):235-243. PubMed ID: 35024885
    [Abstract] [Full Text] [Related]

  • 5. Does the Severity of Overactive Bladder Symptoms Correlate With Risk for Female Sexual Dysfunction?
    Juliato CRT, Melotti IGR, Junior LCS, Britto LGO, Riccetto CLZ.
    J Sex Med; 2017 Jul; 14(7):904-909. PubMed ID: 28622875
    [Abstract] [Full Text] [Related]

  • 6. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
    Tubaro A, Puccini F, De Nunzio C.
    Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873
    [Abstract] [Full Text] [Related]

  • 7. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults.
    Rai BP, Cody JD, Alhasso A, Stewart L.
    Cochrane Database Syst Rev; 2012 Dec 12; 12(12):CD003193. PubMed ID: 23235594
    [Abstract] [Full Text] [Related]

  • 8. An overview of treatment of overactive bladder syndrome in women.
    Allahdin S, Oo N.
    J Obstet Gynaecol; 2012 Apr 12; 32(3):217-21. PubMed ID: 22369391
    [Abstract] [Full Text] [Related]

  • 9. [Impact of overactive bladder on sexual function in women].
    Del Rosso A, Pace G, Di Pierro ED, Masciovecchio S, Galatioto GP, Vicentini C.
    Urologia; 2011 Apr 12; 78(3):200-2. PubMed ID: 21786235
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis.
    Lo CW, Wu MY, Yang SS, Jaw FS, Chang SJ.
    Toxins (Basel); 2020 Feb 18; 12(2):. PubMed ID: 32085542
    [Abstract] [Full Text] [Related]

  • 13. Comparative Efficacy of Neuromodulation Technologies for Overactive Bladder in Adults: A Network Meta-Analysis of Randomized Controlled Trials.
    Huang J, Fan Y, Zhao K, Yang C, Zhao Z, Chen Y, Yang J, Wang T, Qu Y.
    Neuromodulation; 2023 Dec 18; 26(8):1535-1548. PubMed ID: 35989159
    [Abstract] [Full Text] [Related]

  • 14. Shifts in patient preference of third-line overactive bladder therapy after introduction of the implantable tibial nerve stimulator.
    Kapur A, Aalami Harandi A, Hartman-Kenzler J, Kim J.
    Neurourol Urodyn; 2024 Apr 18; 43(4):959-966. PubMed ID: 38390786
    [Abstract] [Full Text] [Related]

  • 15. Overactive Bladder.
    White N, Iglesia CB.
    Obstet Gynecol Clin North Am; 2016 Mar 18; 43(1):59-68. PubMed ID: 26880508
    [Abstract] [Full Text] [Related]

  • 16. Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men.
    De Nunzio C, Brucker B, Bschleipfer T, Cornu JN, Drake MJ, Fusco F, Gravas S, Oelke M, Peyronnet B, Tutolo M, van Koeveringe G, Madersbacher S.
    Eur Urol; 2021 Apr 18; 79(4):492-504. PubMed ID: 33402296
    [Abstract] [Full Text] [Related]

  • 17. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller C.
    Eur Urol; 2013 Aug 18; 64(2):249-56. PubMed ID: 23608668
    [Abstract] [Full Text] [Related]

  • 18. Combination therapy in overactive bladder-untapped research opportunities: A systematic review of the literature.
    Kasman A, Stave C, Elliott CS.
    Neurourol Urodyn; 2019 Nov 18; 38(8):2083-2092. PubMed ID: 31483070
    [Abstract] [Full Text] [Related]

  • 19. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
    Hoag N, Plagakis S, Pillay S, Edwards AW, Gani J.
    Neurourol Urodyn; 2017 Jun 18; 36(5):1377-1381. PubMed ID: 27612039
    [Abstract] [Full Text] [Related]

  • 20. Management of OAB in those over age 65.
    Natalin R, Lorenzetti F, Dambros M.
    Curr Urol Rep; 2013 Oct 18; 14(5):379-85. PubMed ID: 23922134
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.